IBIO · iBio, Inc. · Financials
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed an underwritten public offering raising gross proceeds of approximately $50 million and in January 2026, the Company raised gross proceeds of approximately $26 million in a private placement. Additionally, the Company received gross proceeds of approximately $33.4 million from the exercise of warrants during the year ended June 30, 2026. Based on the total cash and cash equivalents, and investments in debt securities of approximately $88 million at June 30, 2026, the Company believes that its current cash position is sufficient to fund its operations for at least 12 months from the date of filing this Annual Report on Form 10-K for the year ended June 30, 2026 (the “Annual Report”).”View the 10-K filed Aug 28, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $100K | $400K | $225K | $0 | $1.88M | $2.37M | $1.64M | $2.02M | $444K | $394K | $948K | $1.85M | $205K | $1.01M | $1.28M | $520.08K | |
| — | — | — | — | $216K | $1.46M | $703K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $2.17M | $909K | $935K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | 115.02% | 38.34% | 57.08% | — | — | — | — | — | — | — | — | — | |
| $19.64M | $8.31M | $5.19M | $10.33M | $9.83M | $9.99M | $3.57M | $5.47M | $3.99M | $4.12M | $3.16M | $3.5M | $1.9M | $3.43M | $4.98M | $3.08M | |
| $10.6M | $10.69M | $11.67M | $19.02M | $21.75M | $22.03M | $11.37M | $12.33M | $10.69M | $10.55M | $7.69M | $5.02M | $3.89M | $4.24M | $5.62M | $7.09M | |
| $20K | $20K | $20K | $126K | $401K | $291K | $298K | $322K | $341K | $350K | $363K | $358K | $358K | $336K | $323K | $373K | |
| — | — | — | — | — | — | — | $179K | — | — | — | — | — | — | $329.71K | $376.81K | |
| $35.24M | $19M | $16.86M | $29.34M | $31.58M | $32.02M | $14.94M | $17.81M | $14.67M | $14.67M | $10.84M | $8.52M | $4.05M | $7.67M | $10.6M | $10.17M | |
| -$35.14M | -$18.6M | -$16.63M | -$29.34M | -$29.7M | -$31.11M | -$14M | -$15.79M | -$14.23M | -$14.27M | -$9.89M | -$6.67M | -$3.84M | -$6.67M | -$9.33M | -$9.65M | |
| -35141% | -4650.5% | -7392.89% | — | -1576.27% | -1312.15% | -854.88% | -782.36% | -3204.28% | -3622.84% | -1043.57% | -360.13% | -1873.17% | -662.07% | -730.38% | -1856.25% | |
| — | — | — | — | — | — | — | -$15.61M | — | — | — | — | — | — | -$9M | -$9.28M | |
| $53K | $212K | $172K | $83K | $1.41M | $2.45M | $2.47M | $1.9M | $1.92M | $1.93M | $807K | $0 | $0 | $90K | $63K | $50.5K | |
| $2.15M | $437K | $363K | $213K | $177K | $140K | $15K | $75K | $15K | $39K | $22K | $9000 | $8000 | $9000 | $12K | $12.62K | |
| $2.1M | $225K | $1.19M | $32K | $184K | $7.9M | -$2.44M | -$1.81M | -$1.88M | -$1.87M | -$764K | $41K | $174K | $469K | $0 | -$2.49M | |
| -$33.04M | -$18.38M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$33.04M | -$18.38M | -$24.91M | -$65.01M | -$50.3M | -$23.21M | -$16.44M | -$17.59M | -$16.11M | -$14.53M | -$9.76M | -$6.63M | -$3.67M | -$6.2M | -$5.68M | -$12.14M | |
| -33044% | -4594.25% | -11069.78% | — | -2670.01% | -978.79% | -1003.6% | -871.8% | -3627.25% | -3688.32% | -1029.96% | -357.91% | -1788.29% | -615.49% | -444.48% | -2334.73% | |
| — | — | — | — | -$1000 | -$6000 | -$5000 | -$4000 | -$3000 | -$1.61M | -$893K | $0 | — | — | — | — | |
| -$33.04M | -$18.38M | — | -$29.31M | -$29.6M | -$23.47M | -$38.26M | -$17.85M | -$16.37M | -$14.62M | -$9.76M | -$6.63M | -$3.67M | — | — | — | |
| USD/shares | -$0.32 | -$1.75 | -$6.50 | -$106.19 | -$115.60 | -$60.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.32 | -$1.75 | -$6.50 | -$106.19 | -$115.60 | -$60.00 | — | — | — | — | — | — | — | — | — | — |
| shares | 104.06M | 10.5M | 3.83M | 612K | 436.05K | 391.25K | 125.59K | 37.85K | 21.26K | 17.82K | 161.95K | 142.99K | 125.94K | 98.76K | 79.012 | 61.94K |
| shares | 104.06M | 10.5M | 3.83M | 612K | 436.05K | 391.25K | 125.59K | 37.85K | 21.26K | 17.82K | 161.95K | 142.99K | 125.94K | 98.76K | 79.012 | 61.94K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 546,000 | 10-K filed 2026-08-28 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 1,652,000 | 10-K filed 2026-08-28 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 301 similar-size Biotechnology companies (of 532 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Inc | $1,884,000 | $1,098,000 |
| Ibio Cdmo | $499,000 | $1,274,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 |
|---|---|---|
| Collaborative Revenues | $100,000 | $400,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Cdmo | -$20,496,000 | -$16,412,000 |
| Ibio Inc | -$29,194,000 | -$14,699,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 |
|---|---|---|
| Ibio Inc | -1549.6% | -1338.7% |
| Ibio Cdmo | -4107.4% | -1288.2% |